Objective: To develop a practical ultrasonography-guided injection approach to anesthetic blockade of the femoral nerve in calves and to assess the method's accuracy. Animals: 13 cadavers of 4-week-old male Holstein Friesian calves. Procedures: Detailed topographic and anatomic cross-sectional evaluation of the relevant topography in 3 cadavers was performed to identify optimal injection approaches to the femoral nerve. Three approaches (ventral paravertebral, dorsal paravertebral, and ileal) were evaluated by simulated ultrasonography-guided perineural injection of methylene blue dye in 10 cadavers. Ultrasonographic image quality, number of needle redirections required for correct needle positioning, and injection success as defined through a 3-point grading system were recorded. Results: The dorsal paravertebral approach yielded the best results, compared with the ileal and ventral paravertebral approaches, to properly and adequately stain the targeted nerve. Conclusions and Clinical Relevance: The dorsal paravertebral injection technique appeared to be the best choice for performing a femoral nerve block in calves, although this technique will need to be further evaluated in live calves to determine its effectiveness and clinical usefulness. Diagnostic perineural anesthesia of the femoral nerve in cattle might be helpful in identifying quadriceps muscle involvement in those with complex spastic paresis.

The objective of this study was to develop prediction models for the serum IgG concentration in critically ill calves based on indirect assays and to assess if the predictive ability of the models could be improved by inclusion of age, clinical covariates, and/or laboratory covariates. Seventy-eight critically ill calves between 1 and 13 days old were selected from 1 farm. Statistical models to predict IgG concentration from the results of the radial immunodiffusion test, the gold standard, were built as a function of indirect assays of serum and plasma protein concentrations, zinc sulfate (ZnSO4) turbidity and transmittance, and serum γ-glutamyl transferase (GGT) activity. For each assay 4 models were built: without covariates, with age, with age and clinical covariates (infection and dehydration status), and with age and laboratory covariates (fibrinogen concentration and packed cell volume). For the protein models, dehydration status (clinical model) and fibrinogen concentration (laboratory model) were selected for inclusion owing to their statistical significance. These variables increased the coefficient of determination (R2) of the models by ≥ 7% but did not significantly improve the sensitivity or specificity of the models to predict passive transfer with a cutoff IgG concentration of 1000 mg/dL. For the GGT assay, including age as a covariate increased the R2 of the model by 3%. For the ZnSO4 turbidity test, none of the covariates were statistically significant. Overall, the R2 of the models ranged from 34% to 62%. This study has provided insight into the importance of adjusting for covariates when using indirect assays to predict IgG concentration in critically ill calves. Results also indicate that ZnSO4 transmittance and turbidity assays could be used advantageously in a field setting.

Objective: To compare immune responses following modified-live virus (MLV) vaccination at weaning after intranasal or SC administration of an MLV vaccine to beef calves at 2 or 70 days of age. Animals: 184 calves. Procedures: Calves were allocated to 1 of 5 groups. The IN2 (n = 37) and IN70 (37) groups received an MLV vaccine containing bovine herpesvirus 1 (BHV1), bovine viral diarrhea virus (BVDV) types 1 and 2, bovine respiratory syncytial virus (BRSV), and parainfluenza 3 virus intranasally and a Mannheimia haemolytica and Pasteurella multocida bacterin SC at median ages of 2 and 70 days, respectively. The SC2 (n = 36) and SC70 (37) groups received a 7-way MLV vaccine containing BHV1, BVDV1, BVDV2, BRSV, parainfluenza 3 virus, M haemolytica, and P multocida SC at median ages of 2 and 70 days, respectively; the control group (37) remained unvaccinated until weaning. All calves received the 7-way MLV vaccine SC at median ages of 217 (weaning) and 231 days. Serum neutralizing antibody (SNA) titers against BHV1, BVDV1, and BRSV and intranasal IgA concentrations were determined at median ages of 2, 70, 140, 217, and 262 days. Cell-mediated immunity (CMI) against BHV1, BRSV, BVDV1, and P multocida was determined for 16 calves/group. Results: At median ages of 140 and 217 days, BVDV1 SNA titers were significantly higher for the SC70 group than those for the other groups. Intranasal IgA concentrations and CMI increased over time for all groups. Vaccination at weaning increased SNA titers and CMI in all groups. Conclusions and Clinical Relevance: SC administration of an MLV vaccine to 70-day-old calves significantly increased BVDV1 antibody titers before weaning.

Objective—To evaluate the effect of delayed exposure of dairy cattle to Mycobacterium avium subsp paratuberculosis (MAP) on the incidence of those cows testing positive for MAP and developing clinical Johne's disease (CJD). Animals—79 cows not exposed to MAP as calves (unexposed cohort) and 260 cows exposed to MAP as calves (exposed cohort). Procedures—Cows in the unexposed cohort were born into 5 MAP-uninfected herds and introduced at various ages into 5 MAP-infected herds where the exposed cohort cows were born and raised. Beginning when each cow was 24 months old, fecal and serum samples were collected annually from 2003 through 2006. Feces were cultured for MAP, and an ELISA was used to analyze serum samples for antibodies against MAP. Date and reason for culling were obtained from herd records. Incidence of positive culture and ELISA results and CJD was compared between unexposed and exposed cohort cows with Cox regression. Results—Compared with exposed cohort cows, the hazard ratios for unexposed cohort cows having positive culture results, having positive ELISA results, and developing CJD were 0.12, 0.03, and 0.001, respectively, and those ratios increased by 2%, 6%, and 17%, respectively, for each month spent in an MAP-infected herd. Conclusions and Clinical Relevance—Delayed exposure of cows to MAP resulted in lower incidences of positive culture and ELISA results and CJD in those cows, compared with incidences of cows exposed to MAP since birth. The hazard of testing positive for MAP or developing CJD increased with time, regardless of cohort.

Objective-To compare the efficacy of gamithromycin with that of tulathromycin for the treatment of undifferentiated bovine respiratory disease complex (BRDC) in feedlot calves. Animals-1,049 weaned crossbred beef calves. Procedures-At each of 6 feedlots, newly arrived calves with BRDC were administered a single dose of gamithromycin (6.0 mg/kg, SC; n = 523) or tulathromycin (2.5 mg/kg, SC; 526). Case-fatality and BRDC retreatment rates during the first 120 days after treatment, final body weight, and average daily gain (ADG), were compared between treatments. At 2 feedlots, calves were assigned clinical scores for 10 days after treatment to determine recovery rates for each treatment. Bioequivalence limits for gamithromycin and tulathromycin were calculated for outcomes for which there was no significant difference between treatments. Results-Mean BRDC retreatment rate (17.7%) for calves administered gamithromycin was greater than that (9.0%) for calves administered tulathromycin. Mean case-fatality rate, final body weight, ADG, and clinical score 10 days after treatment did not differ significantly between treatments. Limits for mean differences within which gamithromycin was bioequivalent to tulathromycin were +/- 2.4% for case-fatality rate, +/- 13 kg for final body weight, and +/- 0.1 kg/d for ADG. Conclusions and Clinical Relevance-Calves administered gamithromycin had a higher BRDC retreatment rate than did calves administered tulathromycin; otherwise, the clinical efficacy did not differ between the 2 treatments for the treatment of BRDC in feedlot calves.

Objective-To assess a commercially available point-of-care assay for measurement of bovine cardiac troponin I (cTnI) concentration in blood and plasma samples. Sample-Prepared bovine plasma standard samples with known concentrations (0 to 1.0 ng/mL) of cTnI and blood and plasma samples obtained from 28 healthy 2.5-month-old Holstein calves. Procedures-Coefficients of variation were calculated for concentrations of cTnI in prepared standards determined with the point-of-care assay, and values were compared with the known concentrations. The cTnI concentrations in blood samples obtained from calves determined with the point-of-care assay were compared with cTnI concentrations in plasma samples obtained from those animals determined with a validated immunoassay. Results-The coefficients of variation of cTnI concentrations determined for prepared standards by use of the point-of-care assay were low (< 20%) for standards with cTnI concentrations ≥ 0.025 ng/mL. The blood cTnI concentrations determined with the point-of-care assay were not significantly different from the plasma cTnI concentrations determined with the validated immunoassay. Conclusions and Clinical Relevance-Results of this study indicated the point-of-care assay had high precision for determination of cTnI concentrations in most evaluated prepared bovine plasma standard samples. The point-of-care assay may be useful for determination of circulating concentrations of cTnI in cattle.

Objective-To compare pathological changes and viral antigen distribution in tissues of calves with and without preexisting subclinical bovine viral diarrhea virus (BVDV) infection following challenge with bovine herpesvirus-1 (BHV-1). Animals-24 Friesian calves. Procedures-12 calves were inoculated intranasally with noncytopathic BVDV-1a; 12 days later, 10 of these calves were challenged intranasally with BHV-1 subtype 1. Two calves were euthanized before and 1, 2, 4, 7, or 14 days after BHV-1 inoculation. Another 10 calves were inoculated intranasally with BHV-1 only and euthanized 1, 2, 4, 7, or 14 days later. Two calves were inoculated intranasally with virus-free tissue culture fluid and euthanized as negative controls. Pathological changes and viral antigen distribution in various tissue samples from calves with and without BVDV infection (all of which had been experimentally inoculated with BHV-1) were compared. Results-Following BHV-1 challenge, calves with preexisting subclinical BVDV infection had earlier development of more severe inflammatory processes and, consequently, more severe tissue lesions (limited to lymphoid tissues and respiratory and digestive tracts) and greater dissemination of BHV-1, compared with calves without preexisting BVDV infection. Moreover, coinfected calves had an intense lymphoid depletion in the Peyer patches of the ileum as well as the persistence of BVDV in target organs and the reappearance of digestive tract changes during disease progression. Conclusions and Clinical Relevance-In calves, preexisting infection with BVDV facilitated the establishment of BHV-1 infection, just as the presence of BHV-1 favors BVDV persistence, thereby synergistically potentiating effects of both viruses and increasing the severity of the resultant clinical signs.

Objective—To assess biometric tools for gait analysis in healthy calves by use of pressure mat sensors, a handheld algometer, and serial circumferential measurements of selected joints. Animals—20 six- to eight-week-old healthy male Holstein calves. Procedures—Calves were evaluated over a 4-day period. Gait analysis was performed by training calves to walk over a pressure-sensitive mat, which recorded quantitative measurements. An algometer was applied perpendicular to each joint until an aversion response was observed or a preset limit of 50 N/cm2 was obtained. Circumference measurements of the carpal and tarsal joints were obtained by the application of a flexible measuring tape to defined areas of each limb. Variability between joint circumference measurements and pressure mat variables were analyzed with a standard least squares means model. Algometer measurements were dichotomized, and logistic regression was used to assess the probability that a calf reacted to algometer-applied pressure. Results—1 calf was removed from the study because of lameness. Mean carpal and tarsal joint circumference measurements were reliable and consistent among calves. Algometry results suggested that healthy calves were more sensitive to pressure applied to the elbow and stifle joints, compared with pressure applied to the carpal, tarsal, and metacarpophalangeal or metatarsophalangeal joints. Pressure mat variables of stance time and stride velocity varied greatly among calves, whereas impulse and maximum forces varied little. Conclusions and Clinical Relevance—Findings can serve as reference points for other studies and be used for comparison with results for calves with lameness or altered gaits.

Bovine viral diarrhea virus (BVDV) is a widespread bovine pathogen capable of causing disease affecting multiple body systems. Previous studies have shown 2-(2-benzimidazolyl)-5-[4-(2-imidazolino)phenyl]furan dihydrochloride (DB772) effectively prevents BVDV infection in cell culture. The aim of this project was to assess the efficacy of DB772 for the prevention of acute BVDV infection. Four calves seronegative to BVDV were treated with DB772 and another 4 calves were treated with diluent only on the same dosing schedule. Each calf was subsequently challenged intranasally with BVDV. Virus was isolated consistently from untreated calves on days 4 to 8, while treated calves remained negative by virus isolation during this period. Azotemia was exhibited by all treated calves on day 4 resulting in the euthanasia of 1 calf on day 10 and the death of another on day 13. Virus was isolated from the 2 remaining treated calves on day 14 or 21. On day 21, both remaining treated calves and all 4 untreated calves had anti-BVDV antibody titers > 1:2048. This pilot study indicates that DB772 temporarily prevented acute disease due to BVDV, but carries a significant concern of renal toxicity.

Objective-To compare the efficacy of gamithromycin with that of tulathromycin for control of undifferentiated bovine respiratory disease complex (BRDC) in feedlot calves. Animals-2,529 weaned crossbred beef calves. Procedures-At each of 2 feedlots, calves at risk of developing BRDC were administered a single dose of gamithromycin (6.0 mg/kg, SC; n = 1,263) or tulathromycin (2.5 mg/kg, SC; 1,266) metaphylactically. Health (BRDC morbidity, mortality, case-fatality, and retreatment rates) and performance (average daily gain, dry matter intake, and feed-to-gain ratio) outcomes were compared between treatments via classical hypothesis testing. Bioequivalence limits for gamithromycin and tulathromycin were established for outcomes for which no significant difference between treatments was detected. Results-Mean BRDC morbidity rate (31.0%) for calves administered gamithromycin was greater than that (22.9%) for calves administered tulathromycin; otherwise, health and performance did not differ between treatments. Limits for mean differences within which gamithromycin was considered bioequivalent to tulathromycin were +/- 10% for BRDC retreatment rate, +/- 3.5% for BRDC mortality rate, ± 16% for case-fatality rate, +/- 37 kg for final body weight, +/- 0.1 kg/d for average daily gain, +/- 0.3 kg/d for dry matter intake, and +/- 0.7 for feed-to-gain ratio. Conclusions and Clinical Relevance-The efficacy of gamithromycin did not differ from that of tulathromycin for all outcomes except morbidity rate; calves administered gamithromycin had a higher BRDC morbidity rate than did calves administered tulathromycin. On the basis of the bioequivalence limits established for this dataset, gamithromycin was considered equivalent to tulathromycin for the control of BRDC.